Alimentary Pharmacology & Therapeutics
First published: 4 December 2017
DOI: 10.1111/apt.14422
S. Singh, M. Fumery, W. J. Sandborn, M. H. Murad
Objective: There are limited data to inform positioning of agents for treating moderate-severe ulcerative colitis (UC).
Methods: We identified randomised controlled trials (RCTs) in adults with moderate-severe UC treated with anti-TNF agents, anti-integrin agents and janus kinase (JAK) inhibitors, as first-line or second-line agents, and compared with placebo or another active agent.
Comentarios
Para dejar un comentario antes debes iniciar sesión:
¿No tienes una cuenta?
Regístrate a través de éste enlace.